Biodexa Pharmaceuticals (BDRX) announced the appointment of Dr Gary Shangold as Chief Medical Officer with immediate effect. Most recently, Shangold was Chief Medical Officer of Enteris BioPharma, a wholly owned subsidiary of SWK Holdings Corporation (SWKH).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals files to sell 35.875M ADS for holders
- Biodexa Pharmaceuticals Secures Flexible $35 Million Funding Agreement
- Biodexa Pharmaceuticals price target raised to $18 from $8 at Ladenburg
- Biodexa Pharmaceuticals Adjusts Share Value Amid Drug Development Focus
- Biodexa Pharmaceuticals announces result of general meeting